Biology:Prusogliptin
From HandWiki
Short description: Chemical compound
Clinical data | |
---|---|
Other names | DBPR108 |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C16H25FN4O2 |
Molar mass | 324.400 g·mol−1 |
3D model (JSmol) | |
| |
|
Prusogliptin (DBPR108) is an experimental DPP-4 inhibitor developed by CSPC Pharmaceutical Group to treat type 2 diabetes.[1][2][3]
References
- ↑ Xu, Jianping; Ling, Hongwei; Geng, Jianlin; Huang, Yanli; Xie, Ying; Zheng, Huiping; Niu, Huikun; Zhang, Tianhao et al. (November 2022). "Efficacy and safety of DBPR108 (prusogliptin) as an add-on to metformin therapy in patients with type 2 diabetes: A 24-week, multi-centre, randomized, double-blind, placebo-controlled, superiority, phase III clinical trial". Diabetes, Obesity and Metabolism 24 (11): 2232–2240. doi:10.1111/dom.14810. PMID 35791646.
- ↑ Yeh, Kai-Chia; Yeh, Teng-Kuang; Huang, Chung-Yu; Hu, Chih-Bo; Wang, Min-Hsien; Huang, Yu-Wen; Chou, Ling-Hui; Ho, Hsuan-Hui et al. (August 2021). "DBPR108, a novel dipeptidyl peptidase-4 inhibitor with antihyperglycemic activity". Life Sciences 278: 119574. doi:10.1016/j.lfs.2021.119574. PMID 33961850.
- ↑ Wang, Wei; Yao, Jun; Guo, Xiaohui; Guo, Yushan; Yan, Chaoli; Liu, Kuanzhi; Zhang, Ying; Wang, Xiaoyue et al. (2 July 2020). "Efficacy and safety of DBPR108 monotherapy in patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled, phase II clinical trial". Current Medical Research and Opinion 36 (7): 1107–1115. doi:10.1080/03007995.2020.1761311. PMID 32338063.
Original source: https://en.wikipedia.org/wiki/Prusogliptin.
Read more |